Kageaki Watanabe

7PUBLICATIONS
28CO-AUTHORS
Molecular targetsPredictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 20, 2024
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.

Tsuyoshi Hirata, Kageaki Watanabe, Yukio Hosomi

|Dec 20, 2024
Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study.

Takayuki Kobayashi, Kageaki Watanabe, Yukio Hosomi

|Dec 14, 2024
Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study.

Nobuyasu Awano, Kiyotaka Yoh, Kazuhiro Usui

|Aug 19, 2024
High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).

Kageaki Watanabe, Keita Sasaki, Ryunosuke Machida

|Aug 09, 2024
Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study.

Kazuhito Misawa, Kageaki Watanabe, Masahiro Seike

|Jun 18, 2024
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older.

Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata

Pageof 2

Frequent Collaborators

2 joint publications

Yukio Hosomi

2 joint publications

Hidehito Horinouchi

2 joint publications

Yuichiro Ohe

1 joint publications

Shigehiro Yagishita